41 assets in Medulloblastoma

Therapeutic assets addressing Medulloblastoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Irinotecan Medulloblastoma	Pfizer	P2	BB (64)
Olaparib Medulloblastoma	Fundación de investigación HM	P2	BB (64)
Cyclophosphamide Medulloblastoma	Theodore S. Johnson	P2	B (60)
Etoposide Medulloblastoma	Theodore S. Johnson	P2	B (60)
Indoximod Medulloblastoma	Theodore S. Johnson	P2	B (60)
Palbociclib Medulloblastoma	Pfizer	P2	B (57)
PI3K/MTOR INHIBITOR LY3023414 Medulloblastoma	National Cancer Institute (NCI)	P2	B (57)
Tazemetostat Medulloblastoma	National Cancer Institute (NCI)	P2	B (57)
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- Medulloblastoma	National Cancer Institute (NCI)	P2	CCC (53)
Celecoxib Medulloblastoma	Medical University of Vienna	P2	CCC (53)
Cis-Diamminedichloroplatinum Ii Medulloblastoma	St. Jude Children's Research Hospital	P2	CCC (53)
Cytarabine Medulloblastoma	Medical University of Vienna	P2	CCC (53)
Ensartinib Medulloblastoma	National Cancer Institute (NCI)	P2	CCC (53)
Fenofibric Acid Medulloblastoma	Medical University of Vienna	P2	CCC (53)
Ivosidenib Medulloblastoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Medulloblastoma	National Cancer Institute (NCI)	P2	CCC (53)
L-Methionine Medulloblastoma	St. Jude Children's Research Hospital	P2	CCC (53)
Lomustine Medulloblastoma	Theodore S. Johnson	P2	CCC (53)
Nogitecan Medulloblastoma	Pfizer	P2	CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Medulloblastoma	National Cancer Institute (NCI)	P2	CCC (53)
Selpercatinib Medulloblastoma	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Medulloblastoma	National Cancer Institute (NCI)	P2	CCC (53)
Thalidomide Medulloblastoma	Medical University of Vienna	P2	CCC (53)
Ulixertinib Medulloblastoma	National Cancer Institute (NCI)	P2	CCC (53)
(+)-Vincristine Medulloblastoma	Medical University of Vienna	P2	CCC (53)
Vismodegib Medulloblastoma	St. Jude Children's Research Hospital	P2	CCC (53)
Vemurafenib Medulloblastoma	National Cancer Institute (NCI)	P2	CCC (52)
Oxodotreotide Medulloblastoma	Fundación de investigación HM	P1/2	CCC (48)
Polyethyleneglycol-7-Ethyl-10-Hydroxycamptothecin Dfp-13318 Medulloblastoma	National Cancer Institute (NCI)	P1/2	CC (47)
Anti-Egfr Antibody-Drug Conjugate Mrg003 Medulloblastoma	Sun Yat-sen University	P1	CC (43)
b7-h3-car t cells Medulloblastoma	St. Jude Children's Research Hospital	P1	CC (43)
G 207 Medulloblastoma	M.D. Anderson Cancer Center	P1	CC (43)
Ibrutinib Medulloblastoma	Theodore S. Johnson	P1	CC (43)
il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells Medulloblastoma	City of Hope Medical Center	P1	CC (43)
Onc 206 Medulloblastoma	Jazz Pharmaceuticals	P1	CC (43)
Pembrolizumab Medulloblastoma	National Cancer Institute (NCI)	P1	CC (43)
Survaxm Medulloblastoma	Children's Oncology Group	P1	CC (43)
Umitrelimorgene Autodencel Human Lysosomal Associated Membrane Protein 1/Human Cytomegalovirus (Hcmv) 65 Kda Matrix Protein Mrna Medulloblastoma	University of Florida	P1	CC (43)
Val-413 Medulloblastoma	Valent Technologies, LLC	P1	CC (43)
Sotigalimab Medulloblastoma	Pediatric Brain Tumor Consortium	P1	CC (42)
Fimepinostat Medulloblastoma	Sabine Mueller, MD, PhD	Early P1	C (39)